Melissa Stephenson – Page 2

Markets

Hepion Pharma closes $88.4-million offering

Hepion Pharmaceuticals (NASDAQ:HEPA) closed a public offering of 44.2 million common shares at a price of $2 each for gross proceeds of $88.4-million. After deducting underwriting fees and other offering expenses, net...

February 18, 2021

Developments

IntelGenx receives U.S. patent allowance for DisinteQ disintegrating THC oral film

The U.S. Patent and Trademark Office granted a notice of allowance for an IntelGenx (TSXV:IGX; OTCQB:IGXT) patent application entitled, “Film Dosage Form with Extended Release Mucoadhesive Particles.” This film...

February 17, 2021

Markets

SVB Leerink starts Amryt Pharma at OP; PT $40

SVB Leerink launched coverage of Amryt Pharma (NASDAQ:AMYT) with an “outperform” rating and $40 price target. The stock closed at $14.15 on Feb. 12. “Filsuvez is poised to be the first approved treatment for...

February 16, 2021

Executive Moves

Hepion names renowned clinician Dr. Todd Hobbs as CMO

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Todd Hobbs, M.D., to the newly created position of chief medical officer, effective Feb. 16, 2021. In this role, Dr. Hobbs will help lead Hepion as it engages with the FDA...

February 10, 2021

Markets

Maxim ups Cyclo Therapeutics PT to $25 from $12

Maxim Group more than doubled its price target for Cyclo Therapeutics (NASDAQ:CYTH) to $25 from $12, citing updates from the Phase 1 and Phase 1/2 clinical programs for Trapsol Cyclo (TC) in Neimann-Pick Type C (NPC)...

February 9, 2021

Developments

IntelGenx files provisional U.S. patent for VetaFilm high loading oral film platform

IntelGenx (TSXV:IGX; OTCQB:IGXT) filed a new provisional patent application with the U.S. Patent and Trademark Office entitled, “High Loading Oral Film Formulation.” The patent application covers the incorporation of...

February 8, 2021

Markets

Dawson Jones starts Aditxt Therapeutics at buy; PT $14

Dawson Jones Securities initiated coverage of Aditxt Therapeutics (NASDAQ:ADTX) with a “buy” rating and $14 price target. The stock closed at $3.34 on Feb. 3. Aditxt has developed a unique antibody test that measures a...

February 4, 2021

Markets

SVB Leerink starts Cullinan at OP; PT $52

SVB Leerink initiated coverage of Cullinan Management (NASDAQ:CGEM) with an “outperform” rating and $52 price target. The stock closed at $33.77 on Feb. 1. Cullinan is leveraging a unique “Hub-and-Spoke”...

February 2, 2021

Developments

FDA clears Soliton RAP technology for cellulite improvement

The FDA cleared Soliton’s (NASDAQ:SOLY) Rapid Acoustic Pulse (RAP) technology for the short-term improvement in the appearance of cellulite. Soliton’s rapid-pulsed technology safely and comfortably breaks apart the...

February 1, 2021

Markets

Echelon starts Antibe Therapeutics at speculative buy; PT $15 (Canadian)

Echelon Capital Markets initiated coverage of Antibe Therapeutics (TSX:ATE) with a “speculative buy” rating and price target of $15 (Canadian). The stock was quoted at $3.70 in afternoon trading on Jan. 29. Antibe is...

January 29, 2021

Author - Melissa Stephenson

Hepion Pharma closes $88.4-million offering

IntelGenx receives U.S. patent allowance for DisinteQ disintegrating THC oral film

SVB Leerink starts Amryt Pharma at OP; PT $40

Hepion names renowned clinician Dr. Todd Hobbs as CMO

Maxim ups Cyclo Therapeutics PT to $25 from $12

IntelGenx files provisional U.S. patent for VetaFilm high loading oral film platform

Dawson Jones starts Aditxt Therapeutics at buy; PT $14

SVB Leerink starts Cullinan at OP; PT $52

FDA clears Soliton RAP technology for cellulite improvement

Echelon starts Antibe Therapeutics at speculative buy; PT $15 (Canadian)

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter